221 related articles for article (PubMed ID: 34821880)
1. Isatuximab for the treatment of multiple myeloma.
Goldsmith SR; Liu L; Covut F
Drugs Today (Barc); 2021 Nov; 57(11):665-675. PubMed ID: 34821880
[TBL] [Abstract][Full Text] [Related]
2. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Richardson PG; Beksaç M; Špička I; Mikhael J
Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Martin TG; Corzo K; Chiron M; Velde HV; Abbadessa G; Campana F; Solanki M; Meng R; Lee H; Wiederschain D; Zhu C; Rak A; Anderson KC
Cells; 2019 Nov; 8(12):. PubMed ID: 31779273
[TBL] [Abstract][Full Text] [Related]
4. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
6. Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date.
Richter J; Sanchez L; Thibaud S
Semin Oncol; 2020; 47(2-3):155-164. PubMed ID: 32446599
[TBL] [Abstract][Full Text] [Related]
7. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
Shen F; Shen W
Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Leleu X; Martin T; Weisel K; Schjesvold F; Iida S; Malavasi F; Manier S; Chang-Ki Min ; Ocio EM; Pawlyn C; Perrot A; Quach H; Richter J; Spicka I; Yong K; Richardson PG
Ann Hematol; 2022 Oct; 101(10):2123-2137. PubMed ID: 35943588
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
Shah B; Gray J; Abraham I; Chang M
J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
[TBL] [Abstract][Full Text] [Related]
11. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
van de Donk NWCJ; Usmani SZ
Front Immunol; 2018; 9():2134. PubMed ID: 30294326
[TBL] [Abstract][Full Text] [Related]
12. Isatuximab: First Approval.
Dhillon S
Drugs; 2020 Jun; 80(9):905-912. PubMed ID: 32347476
[TBL] [Abstract][Full Text] [Related]
13. CD38 antibodies in multiple myeloma: back to the future.
van de Donk NWCJ; Richardson PG; Malavasi F
Blood; 2018 Jan; 131(1):13-29. PubMed ID: 29118010
[TBL] [Abstract][Full Text] [Related]
14. CD38 targeted treatment for multiple myeloma.
Jelínek T; Mihályová J; Hájek R
Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
16. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
Sunami K; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Kaneko H; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Takahashi K; Tada K; Macé S; Guillemin-Paveau H; Iida S
Cancer Sci; 2020 Dec; 111(12):4526-4539. PubMed ID: 32975869
[TBL] [Abstract][Full Text] [Related]
17. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
[TBL] [Abstract][Full Text] [Related]
18. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
Mikhael J; Richter J; Vij R; Cole C; Zonder J; Kaufman JL; Bensinger W; Dimopoulos M; Lendvai N; Hari P; Ocio EM; Gasparetto C; Kumar S; Oprea C; Chiron M; Brillac C; Charpentier E; San-Miguel J; Martin T
Leukemia; 2020 Dec; 34(12):3298-3309. PubMed ID: 32409691
[TBL] [Abstract][Full Text] [Related]
19. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
20. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]